Thymosin Alpha-1 Specification and Vial Format Review walks through Thymosin Alpha-1 (5mg / 10mg) documentation, vial format, and buyer workflow for Repair & Recovery Research laboratories using sulanpeptide.vip.
Thymosin Alpha-1 is a synthetic 28-amino-acid peptide used in laboratory research on thymic peptide signaling, immune-response models, peptide-mediated cellular pathways, and protein interaction studies.
T-cell proliferation (CFSE dilution), cytokine multiplex panels (IFN-γ, IL-2), and dendritic cell maturation marker flow cytometry are standard immunology readouts. Thymosin alpha-1 appears in hepatitis and oncology vaccine adjuvant research as an immune modulator studied in clinical trial laboratory substudies.
Thymosin alpha-1 modulates T-cell differentiation markers and toll-like receptor signaling in dendritic cell–T-cell co-culture immunology models. Acetylated N-terminal tetrapeptide extension distinguishes Ta1 from other thymic fractions in receptor-independent immunomodulatory assays.
Side-by-side review of specification table, vial label, and COA prevents release errors for Thymosin Alpha-1. Principal investigators should sign off Thymosin Alpha-1 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for Thymosin Alpha-1: CAS 62304-98-7, Formula: C129H215N33O55. MW 3108.3 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for Thymosin Alpha-1 to support reproducibility.
Dose planning for Thymosin Alpha-1 should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Thymosin Alpha-1. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Thymosin Alpha-1 should state whether the lot COA must meet or exceed that threshold for your Repair & Recovery Research assay type.
Specification alignment for Thymosin Alpha-1 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for Thymosin Alpha-1—CAS 62304-98-7, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Thymosin Alpha-1 should include these fields for reproducibility in Repair & Recovery Research journals.
Format selection for Thymosin Alpha-1 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Molecular identifiers for Thymosin Alpha-1—CAS 62304-98-7, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Thymosin Alpha-1 should include these fields for reproducibility in Repair & Recovery Research journals. Format selection for Thymosin Alpha-1 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Specification alignment for Thymosin Alpha-1 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Thymosin Alpha-1 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.